Patel Amends Akari Therapeutics Stake Filing

TL;DR

Patel filed an amendment on Akari Therapeutics (AKTX) shares, check for ownership changes.

AI Summary

Samir Rashmikant Patel filed an amendment (No. 1) to Schedule 13D on November 14, 2024, regarding Akari Therapeutics Plc. This filing indicates a change in the beneficial ownership of the company's ordinary shares, represented by American Depositary Shares. Patel's filing address is listed as 1111 Main Street, Suite 660, Vancouver, WA 98660.

Why It Matters

Changes in beneficial ownership filings like this can signal shifts in major shareholder intentions, potentially impacting stock price and corporate strategy.

Risk Assessment

Risk Level: medium — Amendments to Schedule 13D often indicate significant changes in a major shareholder's position or intentions, which can introduce volatility.

Key Players & Entities

• Samir Rashmikant Patel (person) — Filing person
• Akari Therapeutics Plc (company) — Subject company
• November 14, 2024 (date) — Date of event requiring filing
• 00972G207 (other) — CUSIP Number

FAQ

Key Financial Figures

• $0.0001 — of Issuer) Ordinary Shares, par value $0.0001 per share (represented by American De

Filing Documents

• ea0223686-13da1patel_akari.htm (SC 13D/A) — 49KB
• 0001213900-24-106465.txt ( ) — 50KB

SECURITY AND ISSUER

ITEM 1. SECURITY AND ISSUER. This statement on Schedule 13D relates to the ordinary shares, par value $0.0001 per share (the “Ordinary Shares”) of Akari Therapeutics, Plc, a public limited company formed under the laws of England and Wales (the “Issuer”). The address of the Issuer’s principal executive offices is 22 Boston Wharf Road, FL 7, Boston, Massachusetts, 02210.

IDENTITY AND BACKGROUND

ITEM 2. IDENTITY AND BACKGROUND. (a) Name; Samir R. Patel (the “Reporting Person”). (b) Residence or business address; c/o Akari Therapeutics, Plc., 22 Boston Wharf Road, FL 7, Boston, Massachusetts, 02210. (c) Present principal occupation or employment; Interim Chief Executive Officer, and director of the Issuer. (d) Criminal Convictions: During the past five years, the Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). (e) Civil Proceedings: During the past five years, the Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. (f) Citizenship/State of Incorporation/Organization: United States.

SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION. Prior to the closing of the Merger (as defined below) and the November 2024 Private Placement (as defined below), the Reporting Person purchased an aggregate of 3,411,495,500 Ordinary Shares (represented by American Depositary Shares), 96,774,000 Prefunded Warrants and 1,568,758,000 Ordinary Share Warrants, in various transactions, and was issued (i) 91,396,000 restricted Ordinary Shares and (ii) options to purchase up to 419,034,667 Ordinary Shares which are exercisable within 60 days from the date of this report. Such transactions were reported pursuant to Schedule 13D and Schedule13G under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 16 promulgated under the Exchange Act. On November 14, 2024, the Issuer consummated a series of transactions pursuant to an Agreement and Plan of Merger, dated as of March 4, 2024, as amended, by and among the Issuer, Peak Bio Inc. (“Peak Bio”), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (“Merger Sub”), pursuant to which Merger Sub merged with and into Peak Bio, with Peak Bio surviving as a wholly-owned subsidiary of the Issuer (the “Merger”). At the effective time of the Merger (the “Effective Time”), each issued and outstanding share of common stock of Peak Bio was cancelled and converted into the right to receive 0.2935 ADSs. As such, the Reporting Person received 1,404,622,000 Ordinary Shares from the exchange of Peak Bio shares held by the Reporting Person at the Effective Time. On December 2, 2024, the Issuer closed a private placement of the Issuer’s securities (the “November 2024 Private Placement”). The Reporting Person acquired 419,286,000 Ordinary Shares (represented by American Depositary Shares) and 419,286,000 Ordinary Share Warrants in the November 2024 Private Placement. The funds used by the Reporting Person to acqu

PURPOSE OF TRANSACTION

ITEM 4. PURPOSE OF TRANSACTION. On November 14, 2024, the Reporting Person received the securities in the Merger, and on December 2, 2024, purchased the securities described in the November 2024 Private Placement as described in Item 3 above. Prior to the closing of the Merger and November 2024 Private Placement, the Reporting Person was the owner of the securities as set forth in Item 3 above.

INTEREST IN SECURITIES OF THE ISSUER

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER. The Reporting Person, either in his individual capacity or as sole manager and member of PranaBio Investments LLC, beneficially owns an aggregate of 5,745,834,167 Ordinary Shares (represented by Ordinary Shares or American Depositary Shares), including an aggregate of 419,034,667 options to purchase Ordinary Shares exercisable within 60 days, which represents approximately 10.85% of the Issuer’s Ordinary Shares. The Reporting Person holds sole voting and dispositive power over all securities held by PranaBio Investments LLC. As set forth above, the Reporting Person’s aggregate beneficial Warrants. All Warrants held by the Reporting Person are subject to a 9.99% beneficial ownership limitation. The Reporting Person disclaims beneficial ownership of the securities issuable upon exercise of the Warrants. The percentage of the Reporting Person’s aggregate beneficial Reporting Person by the Issuer.

CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS

ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER. (a), (b) The responses of the Reporting Person with respect to Rows 7 through 13 of the cover page of the Reporting Person to this Schedule 13D are incorporated herein by reference. The percentage of the Reporting Person’s beneficial ownership is based on 52,943,919,523 Ordinary Shares issued and outstanding as of December 3, 2024, as per information provided to the Reporting Person by the Issuer. (c) As described elsewhere in this Form 13D Amendment No. 1, in November 2024, the Reporting Person acquired 1,404,622,000 Ordinary Shares (represented by American Depositary Shares) in the Merger, and 419,286,000 Ordinary Shares (represented by American Depositary Shares) and 419,286,000 Ordinary Share Warrants in the November 2024 Private Placement. (d) Not applicable. (e) Not applicable.

MATERIAL TO BE FILED AS EXHIBITS

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS. Not applicable. 4 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date December 6, 2024 Signature /s/ Samir R. Patel Name Samir R. Patel 5

View Full Filing

View this SC 13D/A filing on SEC EDGAR